SGO 2022


Tisotumab Vedotin | Cervical Cancer

Tisotumab Vedotin (TV) + Carboplatin (Carbo) in First-line (1L) or + Pembrolizumab (Pembro) in Previously Treated (2L/3L) Recurrent or Metastatic Cervical Cancer (r/mCC): Interim Results of ENGOT-Cx8/GOG-3024/innovaTV 205 Study

Tisotumab Vedotin | Cervical Cancer

Real-world treatment pattern and drop-off among recurrent or metastatic cervical cancer patients: a US community oncology-based analysis

Tucatinib | Solid Tumors

SGNTUC-019 Phase 2 basket study of tucatinib and trastuzumab in solid tumors with human epidermal growth factor receptor 2 alterations: uterine and cervical cancer cohorts